Clinical Trials on Refractory Hairy Cell Leukemia

Total 5147 results

AstraZeneca

Approved for marketing

An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia (MOXE)

Relapsed/Refractory Hairy Cell Leukemia
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Systemic Mastocytosis | Recurrent... and other conditions

United States
Joseph Tuscano
National Cancer Institute (NCI); Celgene

Active, not recruiting

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia | Refractory Hairy Cell Leukemia | Refractory Mantle Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
Kite, A Gilead Company

Recruiting

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies (ZUMA-25)

Relapsed/Refractory Waldenstrom Macroglobulinemia | Relapsed/Refractory Richter Transformation | Relapsed/Refractory Burkitt Lymphoma | Relapsed/Refractory Hairy Cell Leukemia

United States, Spain, Germany, Italy, France, Netherlands, Switzerland, Austria
Memorial Sloan Kettering Cancer Center
Yale University; Dana-Farber Cancer Institute

Active, not recruiting

A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia

Leukemia | Leukemia, Hairy Cell | Hairy Cell Leukemia

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI); Northwestern University; Northwell Health; Dana-Farber... and other collaborators

Active, not recruiting

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
MedImmune LLC
Cambridge Antibody Technology

Completed

A Phase I, Multicenter Dose Escalation Study in Patients With Hairy Cell Leukemia

Hairy Cell Leukemia

United States, Poland
National Cancer Institute (NCI)

Terminated

Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia

United States
Jurgen Barth

Completed

Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab

Hairy Cell Leukemia (HCL)

Germany
Power Life Sciences Inc.

Not yet recruiting

Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients

Hairy Cell Leukemia
Scripps Health

Recruiting

Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia

Hairy Cell Leukemia

United States
University of Giessen

Recruiting

Therapy Optimisation for the Treatment of Hairy Cell Leukemia

Hairy Cell Leukemia

Germany
National Cancer Institute (NCI)

Active, not recruiting

Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia

Hairy Cell Leukemia

United States
CHU de Reims

Completed

Rituximab in Hairy Cell Leukemia: a Multicenter Retrospective Study (RITUX-LEUKEMIA)

Hairy-cell Leukemia

France
National Cancer Institute (NCI)

Completed

A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Completed

LMB-2 to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
Cambridge Antibody Technology

Unknown

Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease

Leukemia | Hairy Cell Leukemia | HCL

United States, Poland, United Kingdom
National Cancer Institute (NCI)

Not yet recruiting

Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia

Recurrent Hairy Cell Leukemia | Recurrent Hairy Cell Leukemia Variant
National Cancer Institute (NCI)

Recruiting

Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Active, not recruiting

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

Hairy Cell Leukemia

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer

Recurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Acute Leukemia | Recurrent Acute Lymphoblastic Leukemia | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Acute Lymphoblastic Leukemia | Systemic Mastocytosis | Recurrent Hematologic Malignancy | Hairy Cell Leukemia | Chronic... and other conditions
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
Alexey Danilov, MD
Gilead Sciences; Oregon Health and Science University

Completed

Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma

Anemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Lymphoplasmacytic Lymphoma | Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Richter Syndrome | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Grade 1 Follicular... and other conditions

United States
AstraZeneca
CLL Consortium

Completed

AZD6738 First Time in Patient Multiple Ascending Dose Study

B Cell Lymphomas | 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL), | Prolymphocytic Leukaemia (PLL)

United States
HaEmek Medical Center, Israel

Completed

Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease (B-RAF V600E)

Splenic Marginal Zone Lymphoma | Hairy Cell Leukemia
Swiss Group for Clinical Cancer Research

Completed

Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia

Leukemia

Switzerland
MedImmune LLC

Completed

BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia

Leukemia

United States
Ohio State University Comprehensive Cancer Center
Hairy Cell Leukemia Foundation

Recruiting

Hairy Cell Leukemia Patient Data Registry (HCL-PDR)

Leukemia, Other

United States
MedImmune LLC

Completed

Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia

Leukemia, Hairy Cell

Italy, Spain, United States, Belgium, Poland, Czechia, Germany, Serbia, United Kingdom, France, Israel, Ireland, Canada, Norway
Swiss Group for Clinical Cancer Research

Completed

Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy

Leukemia

Switzerland
Northwestern University
National Cancer Institute (NCI)

Completed

Analysis of Blood and Bone Marrow to Detect Residual Disease in Patients With Previously Treated Hairy Cell Leukemia

Leukemia

United States
AstraZeneca
Iqvia Pty Ltd

Terminated

US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) (PROXY)

Hairy Cell Leukemia

United States
National Cancer Institute (NCI)

Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL) | Hairy Cell Leukemia (HCL) | Cutaneous T Cell Lymphoma (CTCL) | Non-Hodgkins Lymphoma (NHL) | Adult T Cell Lymphoma (ATL)

United States
Sumithira Vasu

Recruiting

Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies

Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditions

United States
University Hospital, Strasbourg, France

Recruiting

B-cell Chronic Lymphoid Malignancies Markers (MALYZOMA-II)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Hairy Cell Leukemia | Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia

France
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia

Recurrent Mantle Cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin... and other conditions

United States
National University of Malaysia
Gaia Science

Recruiting

Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

Relapsed B Acute Lymphoblastic Leukaemia | Refractory B Acute Lymphoblastic Leukaemia

Malaysia
Great Ormond Street Hospital for Children NHS Foundation...
Medical Research Council; UCL Great Ormond Street Institute of Child Health

Recruiting

Base Edited CAR7 T Cells to Treat T Cell Malignancies (TvT CAR7) (TvT CAR7)

Relapsed/Refractory T-cell Acute Lymphoid Leukaemia

United Kingdom
National Cancer Institute (NCI)

Terminated

Sunitinib in Treating Patients With Idiopathic Myelofibrosis

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia... and other conditions

United States
Newave Pharmaceutical Inc

Recruiting

Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

Follicular Lymphoma | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Hairy Cell Leukemia | CLL/SLL

United States
M.D. Anderson Cancer Center
Ziopharm Oncology

Terminated

CD19-Specific T Cells Post AlloSCT

Recurrent Mantle Cell Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory B Acute Lymphoblastic Leukemia | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory... and other conditions

United States
Hospital Infantil Universitario Niño Jesús, Madrid...

Terminated

Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma (HNJ-NKAES-2012)

Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma

Spain
Prelude Therapeutics

Completed

A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies

Adenoid Cystic Carcinoma | Refractory Chronic Myelomonocytic Leukemia | Relapsed/Refractory Acute Myeloid Leukemia | Relapsed/Refractory Mantle Cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Advanced Solid Tumors | Relapsed/Refractory Myelodysplasia | Relapsed...

United States
Virginia Commonwealth University
Gilead Sciences

Withdrawn

Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL (RIVe-CLL/SLL)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
National Cancer Institute (NCI)

Terminated

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Unspecified Childhood Solid Tumor, Protocol Specific | Peripheral T-cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Childhood Chronic Myelogenous Leukemia | Cutaneous B-cell Non-Hodgkin Lymphoma | Hepatosplenic T-cell Lymphoma | Intraocular Lymphoma | Recurrent Childhood Acute Lymphoblastic... and other conditions

United States, Canada

Clinical Trials on Refractory Hairy Cell Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Brazil

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations